Therefore, γδ T cells may require release of additional immune checkpoints such as TIGIT, a potent inhibitor of NK cells.121, 122, 123 The expression of immune checkpoints such as TIGIT, TIM3, LAG3 and NKG2A remains poorly characterised in tumor‐infiltrating γδ T cells and may provide synergistic targets to combine with conventional T‐cell targets such as PD‐1. The gene discussed is TIGIT; the disease is neoplasm.